Abstract
Aim: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome. Patients & methods: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up associations with p < 1 × 10-4 (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE. Results: No new SNPs were found associated with statin response. The GRS was associated with reduced statin response: 0.0394 mmol/l per allele (95% CI: 0.0171-0.0617, p = 5.37 × 10-4). Conclusion: The GRS was associated with statin response, but the small effect size (∼2% of the average low-density lipoprotein cholesterol reduction) limits applicability.
Original language | English (US) |
---|---|
Pages (from-to) | 583-591 |
Number of pages | 9 |
Journal | Pharmacogenomics |
Volume | 17 |
Issue number | 6 |
DOIs | |
State | Published - Apr 2016 |
Bibliographical note
Publisher Copyright:© Future Medicine Ltd 2016.
Keywords
- pharmacogenetics cholesterol
- risk score
- statin therapy